Sensus Healthcare, Inc. (SRTS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 11.13 |
| Open | 12.58 |
| Bid | 13.90 x 1200 |
| Ask | 14.45 x 900 |
| Day's Range | 12.03 - 14.80 |
| 52 Week Range | 3.21 - 14.82 |
| Volume | |
| Avg. Volume | 217,491 |
| Market Cap | 243.967M |
| Beta (5Y Monthly) | 0.78 |
| PE Ratio (TTM) | 11.11 |
| EPS (TTM) | 1.31 |
| Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.30 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SRTS
Related Research
- Sensus Healthcare, Inc.Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, Skyworks soars, Big Biopharma builds immunity to headwinds, and Baidu and the cloud; and Harmonic Drive Systems, Elekta, and Nabtesco.RatingFair ValueEconomic Moat2 months agoMorningstar
- Zacks
Sensus Healthcare, Inc. (SRTS) Q2 Earnings and Revenues Top Estimates
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 16.67% and 17.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Sensus Healthcare Second Quarter 2022 Financial Results Feature Revenue Growth of 124%
Diluted EPS of $0.21 compares with $(0.02) for the year-ago quarter Affirms expectations for full-year profitability Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and six months ended Jun
- GlobeNewswire
Sensus Healthcare Takes Order for 10 TransDermal Infusion Systems™ Supporting Hair Enhancement Centers Expansion Along with U.SK Under Skin’s Hair-Health Serum
BOCA RATON, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of 10 Transdermal Infusion Systems™ to Hair Enhancement Centers (HEC), a rapidly-growing chain of Texas-based hair loss treatment centers. The Systems will be used to non-invasively deliver U.SK Under Skin’s hair-health
